| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1Strategic Director, Cancer Surveillance, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
2Manager, Surveillance Information Services, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
3Vice President, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
4Senior Epidemiologist, Surveillance and Health Policy Research, American Cancer Society, Atlanta, Georgia
5Epidemiologist, Mortality Statistics Branch, Division of Vital Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland
6Vice President Emeritus, Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Georgia
Corresponding author: Ahmedin Jemal, DVM, PhD, Surveillance and Health Policy Research, American Cancer Society, 250 Williams Street, NW, Atlanta, GA 30303-1002; ahmedin.jemal{at}cancer.org
DISCLOSURES: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The authors report no conflicts of interest.
Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are standardized by age to the 2000 United States standard million population. A total of 1,479,350 new cancer cases and 562,340 deaths from cancer are projected to occur in the United States in 2009. Overall cancer incidence rates decreased in the most recent time period in both men (1.8% per year from 2001 to 2005) and women (0.6% per year from 1998 to 2005), largely because of decreases in the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancer sites in women (breast and colorectum). Overall cancer death rates decreased in men by 19.2% between 1990 and 2005, with decreases in lung (37%), prostate (24%), and colorectal (17%) cancer rates accounting for nearly 80% of the total decrease. Among women, overall cancer death rates between 1991 and 2005 decreased by 11.4%, with decreases in breast (37%) and colorectal (24%) cancer rates accounting for 60% of the total decrease. The reduction in the overall cancer death rates has resulted in the avoidance of about 650,000 deaths from cancer over the 15-year period. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year. Although progress has been made in reducing incidence and mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons younger than 85 years of age. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population and by supporting new discoveries in cancer prevention, early detection, and treatment. CA Cancer J Clin 2009. © 2009 American Cancer Society, Inc.
This article has been cited by other articles:
|
|
 |
|
  Y. Wang, T. Romigh, X. He, M. S. Orloff, R. H. Silverman, W. D. Heston, and C. Eng Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines Hum. Mol. Genet., September 2, 2010; (2010) ddq354v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Konoplev, H. A. Fritsche, S. O'Brien, W. G. Wierda, M. J. Keating, T. G. Gornet, S. St Romain, X. Wang, K. Inamdar, M. R. Johnson, et al. High Serum Thymidine Kinase 1 Level Predicts Poorer Survival in Patients With Chronic Lymphocytic Leukemia Am J Clin Pathol, September 1, 2010; 134(3): 472 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Ross, J. Torres-Mora, N. Wagle, T. A. Jennings, and D. M. Jones Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer: Current Perspective Am J Clin Pathol, September 1, 2010; 134(3): 478 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. S. Seeber, R. P. Zweemer, L. Marchionni, L. F. A. G. Massuger, V. T. H. B. M. Smit, W. M. van Baal, R. H. M. Verheijen, and P. J. van Diest Methylation profiles of endometrioid and serous endometrial cancers Endocr. Relat. Cancer, September 1, 2010; 17(3): 663 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-K. Leung, H.-M. Lam, S. Wu, D. Song, L. Levin, L. Cheng, C.-L. Wu, and S.-M. Ho Estrogen receptor {beta}2 and {beta}5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion Endocr. Relat. Cancer, September 1, 2010; 17(3): 675 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zalcman, E. Bergot, and E. Lechapt Update on nonsmall cell lung cancer Eur. Respir. Rev., September 1, 2010; 19(117): 173 - 185. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Armour and C. L. Watkins The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Eur. Respir. Rev., September 1, 2010; 19(117): 186 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Okamoto, T. Mitsudomi, K. Nakagawa, and M. Fukuoka The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations Therapeutic Advances in Medical Oncology, September 1, 2010; 2(5): 301 - 307. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Aroch, S. Kraus, I. Naumov, E. Ron, S. Shapira, D. Kazanov, N. Giladi, A. Litvak, S. Lev-Ari, A. Hallak, et al. Chemopreventive effects of Coltect, a novel dietary supplement, alone and in combination with 5-aminosalicylic acid in 1,2-dimethylhydrazine-induced colon cancer in rats Therapeutic Advances in Gastroenterology, September 1, 2010; 3(5): 281 - 289. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Bruera and D. Hui Integrating Supportive and Palliative Care in the Trajectory of Cancer: Establishing Goals and Models of Care J. Clin. Oncol., September 1, 2010; 28(25): 4013 - 4017. [Full Text] [PDF]
|
|
|
|
|
|
J. Tabernero and J. Baselga Multigene Assays to Improve Assessment of Recurrence Risk and Benefit From Chemotherapy in Early-Stage Colon Cancer: Has the Time Finally Arrived, or Are We Still Stage Locked? J. Clin. Oncol., September 1, 2010; 28(25): 3904 - 3907. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rajpar, C. Massard, A. Laplanche, E. Tournay, M. Gross-Goupil, Y. Loriot, M. Di Palma, A. Bossi, B. Escudier, A. Chauchereau, et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer Ann. Onc., September 1, 2010; 21(9): 1864 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kassie, T. Melkamu, A. Endalew, P. Upadhyaya, X. Luo, and S. S. Hecht Inhibition of lung carcinogenesis and critical cancer-related signaling pathways by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-l-cysteine, indole-3-carbinol and myo-inositol, alone and in combination Carcinogenesis, September 1, 2010; 31(9): 1634 - 1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Wasserman, I. Aneas, and M. A. Nobrega An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer Genome Res., September 1, 2010; 20(9): 1191 - 1197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Bacolod and F. Barany Gene Dysregulations Driven by Somatic Copy Number Aberrations-Biological and Clinical Implications in Colon Tumors: A Paper from the 2009 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2010; 12(5): 552 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Karoor, M. Le, D. Merrick, E. C. Dempsey, and Y. E. Miller Vascular Endothelial Growth Factor Receptor 2-Targeted Chemoprevention of Murine Lung Tumors Cancer Prevention Research, September 1, 2010; 3(9): 1141 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gu, J. A. Ajani, E. T. Hawk, Y. Ye, J. H. Lee, M. S. Bhutani, W. L. Hofstetter, S. G. Swisher, K. K. Wang, and X. Wu Genome-Wide Catalogue of Chromosomal Aberrations in Barrett's Esophagus and Esophageal Adenocarcinoma: A High-Density Single Nucleotide Polymorphism Array Analysis Cancer Prevention Research, September 1, 2010; 3(9): 1176 - 1186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jeronimo and M. Esteller DNA Methylation Markers for Prostate Cancer with a Stem Cell Twist Cancer Prevention Research, September 1, 2010; 3(9): 1053 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Benakanakere, C. Besch-Williford, C. E. Carroll, and S. M. Hyder Synthetic Progestins Differentially Promote or Prevent 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague-Dawley Rats Cancer Prevention Research, September 1, 2010; 3(9): 1157 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Saleiro, G. Murillo, D. B. Lubahn, L. Kopelovich, K. S. Korach, and R. G. Mehta Enhanced Induction of Mucin-Depleted Foci in Estrogen Receptor {beta} Knockout Mice Cancer Prevention Research, September 1, 2010; 3(9): 1198 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Lingen Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers? Cancer Prevention Research, September 1, 2010; 3(9): 1056 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lengyel Ovarian Cancer Development and Metastasis Am. J. Pathol., September 1, 2010; 177(3): 1053 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Park, X. Chen, C. G. Trope, B. Davidson, I.-M. Shih, and T.-L. Wang Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin Am. J. Pathol., September 1, 2010; 177(3): 1087 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamaoka, T. Hara, and M. Kusaka Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer Clin. Cancer Res., September 1, 2010; 16(17): 4319 - 4324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Li and J. L. Abbruzzese New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts Clin. Cancer Res., September 1, 2010; 16(17): 4313 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lauss, M. Ringner, and M. Hoglund Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study Clin. Cancer Res., September 1, 2010; 16(17): 4421 - 4433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Pagliaro, D. L. Williams, D. Daliani, M. B. Williams, W. Osai, M. Kincaid, S. Wen, P. F. Thall, and C. A. Pettaway Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study J. Clin. Oncol., August 20, 2010; 28(24): 3851 - 3857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Thompson, D. P. Ankerst, and C. M. Tangen Prostate-Specific Antigen, Risk Factors, and Prostate Cancer: Confounders Nestled in an Enigma J Natl Cancer Inst, August 19, 2010; (2010) djq313v1. [Full Text] [PDF]
|
|
|
|
|
|
O. Bratt, H. Garmo, J. Adolfsson, A. Bill-Axelson, L. Holmberg, M. Lambe, and P. Stattin Effects of Prostate-Specific Antigen Testing on Familial Prostate Cancer Risk Estimates J Natl Cancer Inst, August 19, 2010; (2010) djq265v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Riggins, M. M. Mazzotta, O. Z. Maniya, and R. Clarke Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response Endocr. Relat. Cancer, August 16, 2010; 17(3): R213 - R231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Sarkar, Y. Li, Z. Wang, and D. Kong Novel targets for prostate cancer chemoprevention Endocr. Relat. Cancer, August 16, 2010; 17(3): R195 - R212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Arcaroli, B. M. Touban, A. C. Tan, M. Varella-Garcia, R. W. Powell, S. G. Eckhardt, P. Elvin, D. Gao, and W. A. Messersmith Gene Array and Fluorescence In situ Hybridization Biomarkers of Activity of Saracatinib (AZD0530), a Src Inhibitor, in a Preclinical Model of Colorectal Cancer Clin. Cancer Res., August 15, 2010; 16(16): 4165 - 4177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Rudloff, L. M. Jacks, J. I. Goldberg, C. A. Wynveen, E. Brogi, S. Patil, and K. J. Van Zee Nomogram for Predicting the Risk of Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ J. Clin. Oncol., August 10, 2010; 28(23): 3762 - 3769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sala, M. Kataoka, N. Pandit-Taskar, N. Ishill, S. Mironov, C. S. Moskowitz, O. Mironov, M. A. Collins, D. S. Chi, S. Larson, et al. Recurrent Ovarian Cancer: Use of Contrast-enhanced CT and PET/CT to Accurately Localize Tumor Recurrence and to Predict Patients' Survival Radiology, August 9, 2010; (2010) radiol.10092279v1. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. S. Groth, N. M. Rueth, J. S. Hodges, E. B. Habermann, R. S. Andrade, J. D'Cunha, and M. A. Maddaus Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. Ann. Thorac. Surg., August 1, 2010; 90(2): 375 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Dave, F. Forsberg, S. Fernandes, C. W. Piccoli, T. B. Fox, D. A. Merton, L. M. Leodore, and A. L. Hall Static and Dynamic Cumulative Maximum Intensity Display Mode for Subharmonic Breast Imaging: A Comparative Study With Mammographic and Conventional Ultrasound Techniques J. Ultrasound Med., August 1, 2010; 29(8): 1177 - 1185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vickers Dutasteride reduces incident prostate cancer in men after negative prostate biopsy Evid. Based Med., August 1, 2010; 15(4): 119 - 120. [Full Text] [PDF]
|
|
|
|
|
|
H. L. Kindler, D. Niedzwiecki, D. Hollis, S. Sutherland, D. Schrag, H. Hurwitz, F. Innocenti, M. F. Mulcahy, E. O'Reilly, T. F. Wozniak, et al. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) J. Clin. Oncol., August 1, 2010; 28(22): 3617 - 3622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gordian, K. Ramachandran, I. M. Reis, M. Manoharan, M. S. Soloway, and R. Singal Serum Free Circulating DNA Is a Useful Biomarker to Distinguish Benign versus Malignant Prostate Disease Cancer Epidemiol. Biomarkers Prev., August 1, 2010; 19(8): 1984 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jemal, M. M. Center, C. DeSantis, and E. M. Ward Global Patterns of Cancer Incidence and Mortality Rates and Trends Cancer Epidemiol. Biomarkers Prev., August 1, 2010; 19(8): 1893 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fassan, M. Pizzi, G. Battaglia, L. Giacomelli, P. Parente, P. Bocus, E. Ancona, and M. Rugge Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis J. Clin. Pathol., August 1, 2010; 63(8): 692 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kawai, S. Sakano, Y. Suehiro, T. Okada, Y. Korenaga, T. Hara, K. Naito, H. Matsuyama, and Y. Hinoda Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma Ann. Onc., August 1, 2010; 21(8): 1612 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chen, M. Chen, and L. S. Barak Development of small molecules targeting the Wnt pathway for the treatment of colon cancer: a high-throughput screening approach Am J Physiol Gastrointest Liver Physiol, August 1, 2010; 299(2): G293 - G300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Chen, J. Gu, G. L. Delclos, A. M. Killary, Z. Fan, M. A. T. Hildebrandt, R. M. Chamberlain, H. B. Grossman, C. P. Dinney, and X. Wu Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients Carcinogenesis, August 1, 2010; 31(8): 1387 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Suh, F. Afaq, N. Khan, J. J. Johnson, F. H. Khusro, and H. Mukhtar Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells Carcinogenesis, August 1, 2010; 31(8): 1424 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Liu, D. Chen, L. Yang, Y. Li, X. Ling, L. Liu, W. Ji, Y. Wei, J. Wang, Q. Wei, et al. A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity Carcinogenesis, August 1, 2010; 31(8): 1405 - 1411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Snyder and S. Greenberg Effect of anaesthetic technique and other perioperative factors on cancer recurrence Br. J. Anaesth., August 1, 2010; 105(2): 106 - 115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Eveno, J. Nemeth, H. Soliman, F. Praz, H. de The, P. Valleur, I. C. Talbot, and M. Pocard Association With a High Number of Lymph Nodes and Microsatellite Instability in Colorectal Cancer--Reply Arch Surg, August 1, 2010; 145(8): 799 - 800. [Full Text] [PDF]
|
|
|
|
|
|
N. D. Facompre, K. El-Bayoumy, Y.-W. Sun, J. T. Pinto, and R. Sinha 1,4-Phenylenebis(Methylene)Selenocyanate, but Not Selenomethionine, Inhibits Androgen Receptor and Akt Signaling in Human Prostate Cancer Cells Cancer Prevention Research, August 1, 2010; 3(8): 975 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Kim, A. R. M. R. Amin, and D. M. Shin Chemoprevention of Head and Neck Cancer with Green Tea Polyphenols Cancer Prevention Research, August 1, 2010; 3(8): 900 - 909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xue, R. Johnson, M. DeSmet, P. W. Snyder, and J. C. Fleet Generation of a Transgenic Mouse for Colorectal Cancer Research with Intestinal Cre Expression Limited to the Large Intestine Mol. Cancer Res., August 1, 2010; 8(8): 1095 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Akisik, K. Sandrasegaran, G. Bu, C. Lin, G. D. Hutchins, and E. G. Chiorean Pancreatic Cancer: Utility of Dynamic Contrast-enhanced MR Imaging in Assessment of Antiangiogenic Therapy Radiology, August 1, 2010; 256(2): 441 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamaguchi, T. Kojima, T. Ito, Y. Kimura, M. Imamura, S. Son, J.-i. Koizumi, M. Murata, M. Nagayama, T. Nobuoka, et al. Transcriptional Control of Tight Junction Proteins via a Protein Kinase C Signal Pathway in Human Telomerase Reverse Transcriptase-Transfected Human Pancreatic Duct Epithelial Cells Am. J. Pathol., August 1, 2010; 177(2): 698 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Merrill and B. D. Hunter Conditional Survival Among Cancer Patients in the United States Oncologist, August 1, 2010; 15(8): 873 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sangha, J. Price, and C. A. Butts Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions Oncologist, August 1, 2010; 15(8): 862 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Hassett The Full Burden of Cancer Oncologist, August 1, 2010; 15(8): 793 - 795. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Taylor, S. Chia, S. Dent, M. Clemons, M. Agulnik, P. Grenci, L. Wang, A. M. Oza, P. Ivy, K. I. Pritchard, et al. A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium Oncologist, August 1, 2010; 15(8): 810 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Triplet, M. D. Shortridge, M. A. Griep, J. L. Stark, R. Powers, and P. Revesz PROFESS: a PROtein Function, Evolution, Structure and Sequence database Database, July 30, 2010; 2010(0): baq011 - baq011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Pickhardt and M. E. Hanson Incidental Adnexal Masses Detected at Low-Dose Unenhanced CT in Asymptomatic Women Age 50 and Older: Implications for Clinical Management and Ovarian Cancer Screening Radiology, July 27, 2010; (2010) radiol.10100511v1. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Bardou, A. Barkun, and M. Martel Effect of statin therapy on colorectal cancer Gut, July 26, 2010; (2010) gut.2009.190900v1. [Abstract] [Full Text]
|
|
|
|
|
|
B. Johanneson, S. K. McDonnell, D. M. Karyadi, P. Quignon, L. McIntosh, S. M. Riska, L. M. FitzGerald, G. Johnson, K. Deutsch, G. Williams, et al. Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus Hum. Mol. Genet., July 22, 2010; (2010) ddq283v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lubner, M. R. Mahoney, J. L. Kolesar, N. K. LoConte, G. P. Kim, H. C. Pitot, P. A. Philip, J. Picus, W.-P. Yong, L. Horvath, et al. Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study J. Clin. Oncol., July 20, 2010; 28(21): 3491 - 3497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Arrieta, C. H. Gonzalez-De la Rosa, E. Arechaga-Ocampo, G. Villanueva-Rodriguez, T. L. Ceron-Lizarraga, L. Martinez-Barrera, M. E. Vazquez-Manriquez, M. A. Rios-Trejo, M. A. Alvarez-Avitia, N. Hernandez-Pedro, et al. Randomized Phase II Trial of All-Trans-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., July 20, 2010; 28(21): 3463 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Y. Wang, Y. X. Li, H. Wang, W. H. Wang, J. Jin, Y. P. Liu, Y. W. Song, S. L. Wang, X. F. Liu, and Z. H. Yu Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma Ann. Onc., July 19, 2010; (2010) mdq347v2. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, L.-E. Wang, L. Mao, M. R. Spitz, and Q. Wei A Functional Variant of Tandem Repeats in Human Telomerase Gene Was Associated with Survival of Patients with Early Stages of Non-Small Cell Lung Cancer Clin. Cancer Res., July 15, 2010; 16(14): 3779 - 3785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wu, W. Chang, J. Zhao, Y. Yu, X. Tan, T. Su, L. Zhao, S. Huang, S. Liu, and G. Cao Development of Autoantibody Signatures as Novel Diagnostic Biomarkers of Non-Small Cell Lung Cancer Clin. Cancer Res., July 15, 2010; 16(14): 3760 - 3768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Bennani-Baiti, A. Cooper, E. R. Lawlor, M. Kauer, J. Ban, D. N. T. Aryee, and H. Kovar Intercohort Gene Expression Co-Analysis Reveals Chemokine Receptors as Prognostic Indicators in Ewing's Sarcoma Clin. Cancer Res., July 15, 2010; 16(14): 3769 - 3778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ng and D. Schrag Microsatellite Instability and Adjuvant Fluorouracil Chemotherapy: A Mismatch? J. Clin. Oncol., July 10, 2010; 28(20): 3207 - 3210. [Full Text] [PDF]
|
|
|
|
|
|
T. D. Gilligan, J. Seidenfeld, E. M. Basch, L. H. Einhorn, T. Fancher, D. C. Smith, A. J. Stephenson, D. J. Vaughn, R. Cosby, and D. F. Hayes American Society of Clinical Oncology Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors J. Clin. Oncol., July 10, 2010; 28(20): 3388 - 3404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, T. Winder, Y. Ning, A. Pohl, D. Yang, M. Kahn, G. Lurje, M. J. LaBonte, P. M. Wilson, M. A. Gordon, et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy Ann. Onc., July 5, 2010; (2010) mdq315v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Asmis, E. Powell, C. S. Karapetis, D. J. Jonker, D. Tu, M. Jeffery, N. Pavlakis, P. Gibbs, L. Zhu, D.- A. Dueck, et al. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care Ann. Onc., July 5, 2010; (2010) mdq309v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Izumi, K. Narimoto, K. Sugimoto, Y. Kobori, Y. Maeda, A. Mizokami, E. Koh, T. Yamada, S. Yano, and M. Namiki The Role of Percutaneous Needle Biopsy in Differentiation of Renal Tumors Jpn. J. Clin. Oncol., July 2, 2010; (2010) hyq076v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Ettinger, W. Akerley, G. Bepler, M. G. Blum, A. Chang, R. T. Cheney, L. R. Chirieac, T. A. D'Amico, T. L. Demmy, A. K. P. Ganti, et al. Non-Small Cell Lung Cancer J Natl Compr Canc Netw, July 1, 2010; 8(7): 740 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. D'Amico Operative Techniques in Early-Stage Lung Cancer J Natl Compr Canc Netw, July 1, 2010; 8(7): 807 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Aggarwal, N. Somaiah, and G. R. Simon Biomarkers with Predictive and Prognostic Function in Non-Small Cell Lung Cancer: Ready for Prime Time? J Natl Compr Canc Netw, July 1, 2010; 8(7): 822 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Dahabreh, H. Linardou, P. Bouzika, V. Varvarigou, and S. Murray TP53 Arg72Pro Polymorphism and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis Cancer Epidemiol. Biomarkers Prev., July 1, 2010; 19(7): 1840 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sun, G.-S. M. Lee, L. Werner, M. Pomerantz, W. K. Oh, P. W. Kantoff, and M. L. Freedman Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy Cancer Epidemiol. Biomarkers Prev., July 1, 2010; 19(7): 1871 - 1878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Wender Family Medicine in the Research Revolution J Am Board Fam Med, July 1, 2010; 23(4): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Chang, J. Donahue, A. Smith, J. Hornick, J. N. Rao, J.-Y. Wang, and R. J. Battafarano Loss of p53, rather than beta-catenin overexpression, induces survivin-mediated resistance to apoptosis in an esophageal cancer cell line J. Thorac. Cardiovasc. Surg., July 1, 2010; 140(1): 225 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Green, H. Horn, and J. M. Erickson Eating Experiences of Children and Adolescents With Chemotherapy-Related Nausea and Mucositis Journal of Pediatric Oncology Nursing, July 1, 2010; 27(4): 209 - 216. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Giovannucci, D. M. Harlan, M. C. Archer, R. M. Bergenstal, S. M. Gapstur, L. A. Habel, M. Pollak, J. G. Regensteiner, and D. Yee Diabetes and Cancer: A consensus report Diabetes Care, July 1, 2010; 33(7): 1674 - 1685. [Full Text] [PDF]
|
|
|
|
|
|
G. L. Jackson, L. D. Melton, D. H. Abbott, L. L. Zullig, D. L. Ordin, S. C. Grambow, N. S. Hamilton, S. Y. Zafar, Z. F. Gellad, M. J. Kelley, et al. Quality of Nonmetastatic Colorectal Cancer Care in the Department of Veterans Affairs J. Clin. Oncol., July 1, 2010; 28(19): 3176 - 3181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Link, F. Balaguer, Y. Shen, T. Nagasaka, J. J. Lozano, C. R. Boland, and A. Goel Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening Cancer Epidemiol. Biomarkers Prev., July 1, 2010; 19(7): 1766 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Paul, A. J. DeCastro, H. J. Lee, A. K. Smolarek, J. Y. So, B. Simi, C. X. Wang, R. Zhou, A. M. Rimando, and N. Suh Dietary intake of pterostilbene, a constituent of blueberries, inhibits the {beta}-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats Carcinogenesis, July 1, 2010; 31(7): 1272 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang and A. Schneider HIF-2{alpha}-mediated activation of the epidermal growth factor receptor potentiates head and neck cancer cell migration in response to hypoxia Carcinogenesis, July 1, 2010; 31(7): 1202 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. CHO, H. YAZICI, H.-C. WU, M. B. TERRY, K. GONZALEZ, M. QU, N. DALAY, and R. M. SANTELLA Aberrant Promoter Hypermethylation and Genomic Hypomethylation in Tumor, Adjacent Normal Tissues and Blood from Breast Cancer Patients Anticancer Res, July 1, 2010; 30(7): 2489 - 2496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. ADAMS, D. L. DEREMER, B. STEVICH, C. A. MATTINGLY, B. GALLT, T. SUBRAMANIAN, J. M. TROUTMAN, and H. P. SPIELMANN Anticancer Activity of Novel Unnatural Synthetic Isoprenoids Anticancer Res, July 1, 2010; 30(7): 2505 - 2512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. SEETHARAM, A. SOOD, A. BASU-MALLICK, L. H. AUGENLICHT, J. M. MARIADASON, and S. GOEL Oxaliplatin Resistance Induced by ERCC1 Up-regulation Is Abrogated by siRNA-mediated Gene Silencing in Human Colorectal Cancer Cells Anticancer Res, July 1, 2010; 30(7): 2531 - 2538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. KIM, J. W. KANG, S. LEE, W. J. CHOI, L. S. JEONG, Y. YANG, J. T. HONG, and D. Y. YOON A3 Adenosine Receptor Antagonist, Truncated Thio-Cl-IB-MECA, Induces Apoptosis in T24 Human Bladder Cancer Cells Anticancer Res, July 1, 2010; 30(7): 2823 - 2830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. IZUMI, A. MIZOKAMI, T. SHIMA, K. NARIMOTO, K. SUGIMOTO, Y. KOBORI, Y. MAEDA, H. KONAKA, E. KOH, and M. NAMIKI Preliminary Results of Tranilast Treatment for Patients with Advanced Castration-resistant Prostate Cancer Anticancer Res, July 1, 2010; 30(7): 3077 - 3081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. LUMACHI, M. FABBRO, A. TREGNAGHI, L. ANTUNOVIC, F. BUI, D. CECCHIN, P. ZUCCHETTA, and A. FASSINA Fine-Needle Aspiration Cytology and 99mTc-pertechnetate Scintigraphy Together in Patients with Differentiated Thyroid Carcinoma Anticancer Res, July 1, 2010; 30(7): 3083 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-H. LIN, Y.-S. LU, C.-H. LIN, D.-Y. CHANG, C.-S. HUANG, A.-L. CHENG, and K.-H. YEH Vinorelbine plus 24-Hour Infusion of High-dose 5-Fluorouracil and Leucovorin as Effective Palliative Chemotherapy for Breast Cancer Patients with Acute Disseminated Intravascular Coagulation Anticancer Res, July 1, 2010; 30(7): 3087 - 3091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Hassen, F. A. Karsan, F. Abbas, Y. Beduk, A. El-Khodary, M. Ghosn, J. Khader, R. Khauli, D. M. Rabah, A. Shamseddine, et al. Modification and Implementation of NCCN GuidelinesTM on Prostate Cancer in the Middle East and North Africa Region J Natl Compr Canc Netw, July 1, 2010; 8(Suppl_3): S-26 - S-28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Deguchi, M. Tanemura, E. Miyoshi, H. Nagano, T. Machida, Y. Ohmura, S. Kobayashi, S. Marubashi, H. Eguchi, Y. Takeda, et al. Increased Immunogenicity of Tumor-Associated Antigen, Mucin 1, Engineered to Express {alpha}-Gal Epitopes: A Novel Approach to Immunotherapy in Pancreatic Cancer Cancer Res., July 1, 2010; 70(13): 5259 - 5269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jiang, N. Chen, F. Zhao, X.-J. Wang, B. Kong, W. Zheng, and D. D. Zhang High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer Cancer Res., July 1, 2010; 70(13): 5486 - 5496. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH |
